Fenway Health, The Fenway Institute, Boston, Massachusetts, USA.
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Sex Transm Infect. 2019 Mar;95(2):83-86. doi: 10.1136/sextrans-2017-053515. Epub 2018 Jun 22.
High-resolution anoscopy (HRA) is a potential screening method for detection of anal cancer precursors. We evaluated factors associated with adherence to recommended HRA follow-up time intervals among men who have sex with men (MSM).
We employed a retrospective, observational cohort study with 155 MSM screened by HRA between 1 April 2011 and 31 March 2016 at a Federally Qualified Health Centre in Boston, Massachusetts.
The sample was 80% white, with a median age of 48 (non-normal distribution, IQR 15). All patients were assigned male sex at birth and none identified as transgender. Fifty patients (32%) followed up with a HRA appointment within 6 months of previous HRA detection of anal high-grade squamous intraepithelial lesion (HSIL). Among patients, 112 (72%) were HIV infected, 56 (36%) had a syphilis diagnosis during the study period, 89 (57.4%) had initiated Hepatitis A or B vaccination series, 70 (45.2%) accessed case management services and 19 (12.3%) utilised pre-exposure prophylaxis (PrEP). In bivariate analysis, patients who underwent recommended follow-up HRA within 6 months of HSIL diagnosis were less likely to report: case management utilisation (p=0.023), initiation of Hepatitis A or B vaccination (p=0.047), HIV diagnosis (p<0.001) and syphilis diagnosis (p=0.001), but were more likely to use HIV PrEP (p<0.001). In binomial logistic regression modelling after adjusting for age and race/ethnicity, patients who had follow-up with HRA within a recommended period of 6 months after HSIL diagnosis were less likely to have initiated Hepatitis A or B vaccination (adjusted OR 0.43, 95% CI 0.20 to 0.94), more likely to use PrEP (adjusted OR 4.47, 95% CI 1.30 to 15.49) and less likely to have a syphilis diagnosis (adjusted OR 0.34, 95% CI 0.14 to 0.86).
Three-quarters of patients with HSIL did not have follow-up HRA within the clinic's recommended follow-up period of 6 months following HSIL diagnosis by HRA. Future studies ought to explore whether addressing anal health during other STI-related care helps improve adherence to recommended time intervals for follow-up HRA. Given the high prevalence of STI and PrEP use, studies might also evaluate whether integrating HRA follow-up with other sexual health screenings helps improve adherence to recommended HRA follow-up.
高分辨率肛门镜检查(HRA)是一种用于检测肛门癌前病变的潜在筛查方法。我们评估了男男性行为者(MSM)中与遵循推荐的 HRA 随访时间间隔相关的因素。
我们采用了回顾性、观察性队列研究,纳入了 2011 年 4 月 1 日至 2016 年 3 月 31 日期间在马萨诸塞州波士顿的一家联邦合格健康中心接受 HRA 筛查的 155 名 MSM。
该样本中 80%为白人,中位年龄为 48 岁(非正态分布,IQR 15)。所有患者均在出生时被分配为男性,且均未被认定为跨性别者。50 名患者(32%)在先前的 HRA 检测到肛门高级别鳞状上皮内病变(HSIL)后 6 个月内进行了 HRA 随访预约。在患者中,112 名(72%)感染了 HIV,56 名(36%)在研究期间被诊断患有梅毒,89 名(57.4%)开始了甲型或乙型肝炎疫苗接种系列,70 名(45.2%)接受了病例管理服务,19 名(12.3%)使用了暴露前预防(PrEP)。在单变量分析中,在 HSIL 诊断后 6 个月内接受推荐的 HRA 随访的患者不太可能报告:病例管理的使用(p=0.023)、甲型或乙型肝炎疫苗接种的开始(p=0.047)、HIV 诊断(p<0.001)和梅毒诊断(p=0.001),但更有可能使用 HIV PrEP(p<0.001)。在调整年龄和种族/民族后进行二项逻辑回归模型分析,在 6 个月的推荐时间内进行 HRA 随访的患者不太可能开始甲型或乙型肝炎疫苗接种(调整后的 OR 0.43,95%CI 0.20 至 0.94),更有可能使用 PrEP(调整后的 OR 4.47,95%CI 1.30 至 15.49),并且不太可能患有梅毒(调整后的 OR 0.34,95%CI 0.14 至 0.86)。
三分之二的 HSIL 患者在 HRA 诊断后 6 个月内未按照诊所推荐的随访时间进行 HRA 随访。未来的研究应该探讨在其他性传播感染相关护理期间关注肛门健康是否有助于提高对 HRA 随访推荐时间间隔的依从性。鉴于性传播感染和 PrEP 使用的高患病率,研究也可能评估在其他性健康筛查中整合 HRA 随访是否有助于提高对推荐的 HRA 随访的依从性。